Literature DB >> 8735631

Analysis of the activity of alpha 1-adrenoceptor antagonists in rat aorta.

P H Van der Graaf1, N P Shankley, J W Black.   

Abstract

1. In this study, the effect of seven alpha 1-adrenoceptor antagonists (tamsulosin, phentolamine, prazosin, WB-4101, 5-methylurapidil, spiperone and HV723) have been examined on the contractile response to noradrenaline (NA) and phenylephrine (PE) in rat isolated aorta. 2. NA and PE, when administered using a cumulative dosing schedule, both produced concentration-dependent contraction of aortic rings. It was possible to fit the individual concentration-effect (E/[A]) curve data to the Hill equation to provide estimates of the curve midpoint location (p[A]50 = 7.74 +/- 0.10 and 7.14 +/- 0.18), midpoint slope (nH = 0.82 +/- 0.03 and 0.99 +/- 0.10) and upper asymptote (alpha = 3.2 +/- 0.3 and 3.1 +/- 0.2 g) parameters for NA and PE, respectively. However, the Hill equation provided a better fit to the E/[A] curve data obtained with another contractile agent, 5-hydroxytryptamine (5-HT) (p[A50] = 6.09 +/- 0.08, nH = 1.49 +/- 0.09, alpha = 2.6 +/- 0.3 g), as judged by calculation of the mean sum of squares of the differences between the observed and predicted values. 3. All of the antagonists investigated produced concentration-dependent inhibition of the contractile responses of the aorta to NA and PE. Although no significant effects on the upper asymptotes of the E/[A] curves of any of the antagonists tested were detected, only tamsulosin and 5-methylurapidil did not have a significant effect on the slope (nH) of the NA and PE E/[A] curves. The other antagonists produced significant steepening of the curves obtained with NA and/or PE. 4. Notwithstanding the fact that one of the basic criteria for simple competitive antagonism at a single receptor class was not always satisfied, the individual log [A]50 values estimated in the absence and presence of antagonist within each experiment were fitted to the competitive model. The Schild plot slope parameters for the antagonism of NA and PE by phentolamine and HV723 were found to be significantly less than unity. The Schild plot slope parameters for the other antagonists were not significantly different from unity. 5. In the absence of evidence to suggest that the deviations from simple competitive antagonism were due to failure to satisfy basic experimental conditions for quantitative analysis, an attempt was made to see whether the data could be accounted for by an existing two-receptor model (Furchgott, 1981). The goodness-of-fit obtained with the two-receptor model was significantly better than that obtained with the one-receptor model. Furthermore, with the exception of the data obtained with phentolamine, the pKB estimates for the two receptors were independent of whether NA or PE was used as agonist. 6. To determine which alpha 1-adrenoceptor subtypes may be associated with those defined by the two receptor model, the mean pKB estimates obtained from the two-receptor model fit were compared with affinities measured by Laz et al. (1994) for rat cloned alpha 1-adrenoceptor subtypes expressed in COS-7 cells. The sum of squared differences of the data points from the line of identity was smallest for both pKB1 and pKB2 in the case of the alpha 1a/d-adrenoceptor (now referred to as alpha 1d-adrenoceptor; Hieble et al., 1995). Therefore, the complexity exposed in this study may be due to the expression of closely-related forms of the alpha 1d-adrenoceptor. However, relatively good matches were also found between pKB1 and alpha 1c and between pKB2 and alpha 1b. Therefore, on the basis of these data, it is not possible to rule out the involvement of all three alpha 1-adrenoceptors. The conflicting reports concerning the characteristics of the alpha 1-adrenoceptor population mediating contraction of the rat aorta may, at least in part, be due to the lack of highly selective ligands and to between-assay variation in the expression of multiple alpha 1-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735631      PMCID: PMC1909637          DOI: 10.1111/j.1476-5381.1996.tb15403.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

1.  Pharmacologic characterization of cloned alpha 1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype.

Authors:  D A Schwinn; J W Lomasney
Journal:  Eur J Pharmacol       Date:  1992-12-01       Impact factor: 4.432

2.  Distribution of alpha 1C-adrenergic receptor mRNA in adult rat tissues by RNase protection assay and comparison with alpha 1B and alpha 1D.

Authors:  D G Rokosh; B A Bailey; A F Stewart; L R Karns; C S Long; P C Simpson
Journal:  Biochem Biophys Res Commun       Date:  1994-05-16       Impact factor: 3.575

3.  The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.

Authors:  C Forray; J A Bard; J M Wetzel; G Chiu; E Shapiro; R Tang; H Lepor; P R Hartig; R L Weinshank; T A Branchek
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

4.  Cardiovascular effects of chloroethylclonidine, an irreversible alpha 1B-adrenoceptor antagonist, in the unanesthetized rat: a pharmacological analysis in vivo and in vitro.

Authors:  H M Vargas; D Cunningham; L Zhou; H B Hartman; A J Gorman
Journal:  J Pharmacol Exp Ther       Date:  1993-08       Impact factor: 4.030

5.  Alpha 1-adrenoceptor subtype in the rat prostate is preferentially the alpha 1A type.

Authors:  H Yazawa; K Honda
Journal:  Jpn J Pharmacol       Date:  1993-07

6.  Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors.

Authors:  A J Sleight; W Koek; D C Bigg
Journal:  Eur J Pharmacol       Date:  1993-07-20       Impact factor: 4.432

7.  Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen.

Authors:  R Aboud; M Shafii; J R Docherty
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

8.  Pharmacological properties of the cloned alpha 1A/D-adrenoceptor subtype are consistent with the alpha 1A-adrenoceptor characterized in rat cerebral cortex and vas deferens.

Authors:  B A Kenny; A M Naylor; P M Greengrass; M J Russell; S J Friend; A M Read; M G Wyllie
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

9.  Functional distribution and role of alpha-1 adrenoceptor subtypes in the mesenteric vasculature of the rat.

Authors:  J Q Kong; D A Taylor; W W Fleming
Journal:  J Pharmacol Exp Ther       Date:  1994-03       Impact factor: 4.030

10.  Subtypes of alpha 1-adrenoceptors in rat blood vessels.

Authors:  C Han; J Li; K P Minneman
Journal:  Eur J Pharmacol       Date:  1990-11-06       Impact factor: 4.432

View more
  8 in total

1.  Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1L- and alpha1A-adrenoceptors.

Authors:  S Morishima; F Suzuki; H Yoshiki; A S Md Anisuzzaman; Z S Sathi; T Tanaka; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

2.  Analysis of the action of idazoxan calls into question the reliability of the rat isolated small mesenteric artery assay as a predictor for alpha 1-adrenoceptor-mediated pressor activity.

Authors:  P H Van der Graaf; N P Shankley; J W Black
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

3.  In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.

Authors:  T J Williams; D R Blue; D V Daniels; B Davis; T Elworthy; J R Gever; M S Kava; D Morgans; F Padilla; S Tassa; R L Vimont; C R Chapple; R Chess-Williams; R M Eglen; D E Clarke; A P Ford
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Microphysiometric analysis of human alpha1a-adrenoceptor expressed in Chinese hamster ovary cells.

Authors:  T Taniguchi; R Inagaki; S Murata; I Akiba; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor "knockdown" in vivo.

Authors:  M Garrido; J Gubbens-Stibbe; E Tukker; E Cox; J von Frijtag; D Künzel; A IJzerman; M Danhof; P H van der Graaf
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

6.  A possible structural determinant of selectivity of boldine and derivatives for the alpha 1A-adrenoceptor subtype.

Authors:  Y Madrero; M Elorriaga; S Martinez; M A Noguera; B K Cassels; P D'Ocon; M D Ivorra
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

7.  Pharmacological properties of a wide array of ergolines at functional alpha(1)-adrenoceptor subtypes.

Authors:  Tilo Görnemann; Sven Jähnichen; Björn Schurad; Klaus Peter Latté; Reinhard Horowski; Johannes Tack; Miroslav Flieger; Heinz H Pertz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-08       Impact factor: 3.000

8.  Functional characterization of alpha 1-adrenoceptor subtypes in vascular tissues using different experimental approaches: a comparative study.

Authors:  Regina Gisbert; Yolanda Madrero; Valentina Sabino; M Antonia Noguera; M Dolores Ivorra; Pilar D'Ocon
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.